Nasal hepatitis b vaccine composition and method for producing same

Abstract

The present invention relates to a hepatitis B vaccine composition for nasal mucosa spraying administration, characterized by comprising a hepatitis B antigen and a gel base containing a carboxyl vinyl polymer, and by being applicable to hepatitis B prevention and treatment.

Description

technical field [0001] The invention relates to a hepatitis B vaccine composition and its technology for nasal mucosal spray administration to prevent and treat hepatitis B. Background technique [0002] Hepatitis B is hepatitis caused by infection with the hepatitis B virus (HBV), which is transmitted through blood or body fluids. Persistent infection of liver cells by HBV can cause chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. [0003] Chronic hepatitis B (CHB) is currently treated mainly by using interferon agents (IFN) or nucleoside analog agents (NA) as first-line therapy. In IFN therapy, some effective examples have been reported, which increase immunity to effectively maintain the growth suppression of the virus, but in general, IFN therapy has a low HBV clearance rate and strong side effects, which is a big problem. On the other hand, NA therapy has a high HBV clearance rate of about 95%, but the therapeutic effect is temporary and cannot bring ...

AI Technical Summary

Problems solved by technology

However, in its method of administration, it needs to be used in conjunction with subcutaneous vaccination to obtain an adequate immune response, i.e. it is a two-cycle vaccination, not a complete vaccine for nasal mucosal administration

[0007] As described above, as a next-generation hepatitis B vaccine, a nasal vaccine formulation that is widely used as an HBV vaccine for treatment and prevention is expected, but has not yet been completely successful

Images